Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.54 |
| ▸ | NPC1 | O15118 | 4/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.46 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | NOS1 | P29475 | 2/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13900769 | 0.83 | RAB9A (0.53) | RAB9ASMN1; SMN2NPC1MAPTALDH1A1 | |
| SCHEMBL958545 | 0.80 | — | — | |
| Hydrochloric Acid SCHEMBL4796242 | 0.79 | SMN1; SMN2 (0.53) | RAB9ASMN1; SMN2NPC1MAPTALDH1A1 | |
| SCHEMBL31093366 | 0.79 | SMN1; SMN2 (0.49) | RAB9ASMN1; SMN2NPC1MAPTALDH1A1 | |
| SCHEMBL12126197 | 0.78 | PKM (0.44) | RAB9ASMN1; SMN2NPC1MAPTALDH1A1 | |
| Hydrochloric Acid SCHEMBL4780449 | 0.78 | RAB9A (0.60) | RAB9ASMN1; SMN2NPC1MAPTALDH1A1 | |
| SCHEMBL436856 | 0.78 | — | — | |
| SCHEMBL91420 | 0.77 | — | — | |
| SCHEMBL9892952 | 0.76 | SMN1; SMN2 (0.47) | RAB9ASMN1; SMN2NPC1MAPTALDH1A1 | |
| SCHEMBL6363647 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7411071-B2 | Modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-08-12 | — | — | US | disclosed |
| EP-1844028-A1 | MODULATORS OF THE GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF | Bristol-Myers Squibb Company (US) | 2007-10-17 | — | — | EP | disclosed |
| WO-2006076633-A1 | MODULATORS OF THE GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-κB ACTIVITY AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-07-20 | — | — | WO | disclosed |
| US-20060154975-A1 | Modulators of the glucocorticoid receptor, AP-1, and/or NF-kB activity and use thereof | BRISTOL-MYERS SQUIBB COMPANY | 2006-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060154975-A1 | Modulators of the glucocorticoid receptor, AP-1, and/or NF-kB activity and use thereof | NR3C1, RCOR1, NFRKB | RAB9A 1806/4885SMN1; SMN2 4825/4885NPC1 1300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.